Cited 5 times in
Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이용찬 | - |
dc.date.accessioned | 2023-08-09T02:53:09Z | - |
dc.date.available | 2023-08-09T02:53:09Z | - |
dc.date.issued | 2017-11 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195906 | - |
dc.description.abstract | Background: Most international guidelines recommend triple-therapy regimens consisting of a proton pump inhibitor, clarithromycin, and amoxicillin/metronidazole for at least 7 days for the eradication of Helicobacter pylori. However, the efficacy of 7-day clarithromycin-based standard triple therapy for H. pylori infection is currently unacceptable in Korea. In this study, we will compare the efficacy and safety of 7-day standard triple therapy, 10-day sequential therapy, and 10-day concomitant therapy for the first-line treatment of H. pylori infection in Korea. Methods/design: In this multicenter, investigator-blinded, randomized trial we are recruiting adult patients with H. pylori infection from 15 hospitals in Korea to determine whether sequential or concomitant treatment is superior to standard triple therapy. Patients are randomly assigned to receive either standard triple therapy (lansoprazole, amoxicillin, and clarithromycin) for 7 days, or sequential treatment (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin, and metronidazole for another 5 days) for 10 days, or concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole) for 10 days. The primary outcome is the rate of H. pylori eradication in the intention-to-treat population. Discussion: The results of this study will be crucial for determining the optimal regimen for the primary treatment of H. pylori infection in Korea. This study will produce vital evidence that will lead to revisions to guidelines concerning first-line treatment regimens for H. pylori infection. Trial registration: Clinical Research Information Service (CRIS), Republic of Korea, KCT0001980 . Registered on 25 July 2016. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | TRIALS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Amoxicillin / administration & dosage | - |
dc.subject.MESH | Amoxicillin / adverse effects | - |
dc.subject.MESH | Clarithromycin / administration & dosage | - |
dc.subject.MESH | Clarithromycin / adverse effects | - |
dc.subject.MESH | Clinical Protocols* | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Helicobacter Infections / drug therapy* | - |
dc.subject.MESH | Helicobacter pylori* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lansoprazole / administration & dosage | - |
dc.subject.MESH | Lansoprazole / adverse effects | - |
dc.subject.MESH | Metronidazole / administration & dosage | - |
dc.subject.MESH | Metronidazole / adverse effects | - |
dc.subject.MESH | Sample Size | - |
dc.title | Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyuk Lee | - |
dc.contributor.googleauthor | Beom Jin Kim | - |
dc.contributor.googleauthor | Sang Gyun Kim | - |
dc.contributor.googleauthor | Jin Il Kim | - |
dc.contributor.googleauthor | Il Ju Choi | - |
dc.contributor.googleauthor | Yong Chan Lee | - |
dc.contributor.googleauthor | Jae G Kim | - |
dc.contributor.googleauthor | Jae J Kim | - |
dc.contributor.googleauthor | Korean College of Helicobacter and Upper Gastrointestinal Research | - |
dc.identifier.doi | 10.1186/s13063-017-2281-0 | - |
dc.contributor.localId | A02988 | - |
dc.contributor.localId | A02982 | - |
dc.relation.journalcode | J02759 | - |
dc.identifier.eissn | 1745-6215 | - |
dc.identifier.pmid | 29149904 | - |
dc.subject.keyword | Concomitant therapy | - |
dc.subject.keyword | Helicobacter pylori | - |
dc.subject.keyword | Sequential therapy | - |
dc.subject.keyword | Triple therapy | - |
dc.contributor.alternativeName | Lee, Yong Chan | - |
dc.contributor.affiliatedAuthor | 이용찬 | - |
dc.citation.volume | 18 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 549 | - |
dc.identifier.bibliographicCitation | TRIALS, Vol.18(1) : 549, 2017-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.